Most pathogenic mtDNA mutations are heteroplasmic and there is a clear correlation between high levels of mutated mtDNA in a tissue and pathology. We have found that in vivo double-strand breaks (DSBs) in mtDNA lead to digestion of cleaved mtDNA and replication of residual mtDNA. Therefore, if DSB could be targeted to mutations in mtDNA, mutant genomes could be eliminated and the wild-type mtDNA would repopulate the cells. This can be achieved by using mitochondria-targeted restriction endonucleases as a means to degrade specific mtDNA haplotypes in heteroplasmic cells or tissues. In this work, we investigated the potential of systemic delivery of mitochondriatargeted restriction endonucleases to reduce the proportion of mutant mtDNA in specific tissues. Using the asymptomatic NZB/ BALB mtDNA heteroplasmic mouse as a model, we found that a mitochondria-targeted ApaLI (that cleaves BALB mtDNA at a single site and does not cleave NZB mtDNA) increased the proportion of NZB mtDNA in target tissues. This was observed in heart, using a cardiotropic adeno-associated virus type-6 (AAV6) and in liver, using the hepatotropic adenovirus type-5 (Ad5). No mtDNA depletion or loss of cytochrome c oxidase activity was observed in any of these tissues. These results show the potential of systemic delivery of viral vectors to specific organs for the therapeutic application of mitochondria-targeted restriction enzymes in mtDNA disorders.
Introduction
Recent epidemiological studies indicate that mtDNArelated diseases have a prevalence of 9.2 per 100 000. 1 In addition, these disorders constitute one of the most common neurometabolic diseases of childhood, with a risk of developing mitochondrial disease of 1 in 5000, 2 making them a common cause of morbidity. 3 Mitochondrial diseases can affect multiple tissues, have variable severity and heterogeneous clinical expression, not only among individuals with different mutations, but also among individuals with the same mutation. 4 Cardiomyopathy is diagnosed in B17-40% of pediatric patients with mitochondrial disorders 5, 6 and the presence of cardiomyopathy is indicative of poor prognosis, particularly among patients with cytochrome c oxidase (COX) deficiency. 6 Approximately 27% of patients with mitochondrial cardiomyopathy are found to carry heteroplasmic mtDNA point mutations. 7 Eighteen heteroplasmic point mutations have been associated with cardiomyopathies, 11 of which fall within tRNA Leu(UUR) or tRNA Ile , the latter appearing to be a hotspot for mutations, leading to isolated or primary mitochondrial cardiomyopathy. 6 Hepatopathies are seen in between 10 and 20% of pediatric patients with mitochondrial disease, 8 being less frequently associated with heteroplasmic mtDNA point mutations than cardiomyopathies. Hepatopathy can be a feature of some common multisystem disorders caused by heteroplasmic mtDNA mutations, such as MERRF. 9 Normal expression of the mitochondrial genome (mtDNA) is essential for the biogenesis of the oxidative phosphorylation system (OXPHOS). Tissues from patients with heteroplasmic mtDNA mutations contain mtDNA populations with variable proportions of mutant and wild-type mtDNA. 10 Disease phenotypes are only observed once the percentage of wild-type mtDNA drops below a threshold level, and because of this, increasing the proportion of wild-type mtDNA in affected tissues by inducing a so-called 'heteroplasmy shift,' is seen as a therapeutic strategy for mtDNA disorders. 11, 12 Ours and other groups have successfully induced heteroplasmy shift by delivering restriction endonucleases (REs) that target specific mtDNA subpopulations in mitochondria. Cleaved mtDNA is rapidly degraded allowing repopulation with uncleaved mtDNA. 13 Using this approach, levels of the pathogenic 8993T-G mutation (MT-ATP6) have been reduced in heteroplasmic cybrid cells using SmaI 14 and XmaI 15 that target the mutation. Working with asymptomatic heteroplasmic mice that carry NZB and BALB murine mtDNA haplotypes, we have previously shown that a localized heteroplasmy shift can be induced following intra-tissue injection of viral vectors expressing mitochondriatargeted RE (mito-RE). 13, 16 Heart and liver are both accessible to systemically administered viral vectors, and this prompted us to investigate whether heteroplasmy shift could be induced in these two disease-relevant organs following systemic delivery of viral vectors expressing mitochondria-targeted RE.
To target mitochondrial RE to the heart, we used AAV6 vectors that have a well-characterized tropism for heart 17 and to a lesser extent liver and skeletal muscle. 18 Recombinant adenoviral vectors were used to target the liver as they are highly hepatotropic when administered intravenously. 19 NZB/BALB heteroplasmic mice were used as a model of heteroplasmy and ApaLI (mito-ApaLI-HA) as the mito-RE.
Results

mtDNA segregation patterns in NZB/BALB heteroplasmic mice
Earlier characterization of mice harboring two types of mtDNA (NZB and BALB) mice has shown an uneven segregation of mtDNA haplotypes in liver, spleen, and kidney but not in muscle. 20 We confirmed the skewed natural segregation of the NZB mtDNA haplotype over 22 months in this heteroplasmic mouse model showing increases in NZB mtDNA in liver and kidney, and decreases in spleen, relative to the amount of NZB mtDNA from ear samples of the same mice obtained at the time of genotyping (3-4 weeks) . No changes in the levels of NZB mtDNA were detected in ear samples over time (Supplementary Figure S1 ).
Mito-ApaLI-HA expressed from AAV6 vectors is targeted to mitochondria
We have previously shown that mito-ApaLI-HA expressed from Ad5 vectors is directed to mitochondria. 13 To confirm that mito-ApaLI-HA expressed from AAV6 vectors (Supplementary Figure S2) is also targeted to mitochondria, cultured mouse hepatocytes were infected with rAAV6[mito-ApaLI-HA] and analyzed 1 week post-transduction by immunocytochemistry. Cells transduced with rAAV6[mito-ApaLI-HA] showed HA expression that colocalized with the mitochondrial dye Mito Tracker Red CMXRos (Supplementary Figure S3 ).
Cardiac expression of rAAV6[mito-ApaLI-HA]
Following intra-jugular injection of 1-5 Â 10e11 vector genome particles (vg)/mouse, the expression of the rAAV6[mito-ApaLI-HA] and the control expressing alkaline phosphatase rAAV6[AP] were analyzed at 2, 8, and 12 weeks post-injection (two animals per group). In animals injected with the alkaline phosphatase vector, activity was detectable mainly in heart, and only at 8 and 12 weeks ( Figure 1a ). Expression of mito-ApaLI-HA in heart was detectable by immunocytochemistry staining with an anti-HA antibody after 8, and 12 weeks, whereas liver ( Figure 1b ) and skeletal muscle (not shown) only showed focal positive staining at 12 weeks. Expression of mito-ApaLI-HA was positive in heart and liver by western blot at 2 weeks post-injection and remained detectable at 8 and 12 weeks post-injection ( Figure 1c ).
On the other hand, expression of mito-ApaLI-HA was barely detectable in skeletal muscle (M), brain (B), lung (Lu), and spleen (S) at 12 weeks post-injection ( Figure 1c ).
Liver expression of rAd5[mito-ApaLI-HA]
Similar injections were carried out using 3 Â 10e9 vg/ mouse of the rAd5[mito-ApaLI-HA] (six animals) or control rAd5[eGFP] (three animals). Using immunofluorescence, expression of mito-ApaLI-HA was visible from 1 week post-injection (Figure 2a ). In animals that received control vector, direct visualization of eGFP expression was also possible at 1 week post-injection (Figure 2a ).
Cardiac expression of rAAV6[mito-ApaLI-HA]-no mtDNA depletion nor COX deficiency observed in heteroplasmic mice
One concern related to the use of mito-RE is the potential for the rapid mtDNA cleavage to cause an mtDNA depletion. For this reason, Southern blots were used to determine mtDNA/nDNA ratios in vector-positive tissues. No evidence of mtDNA depletion (as a ratio to the nuclear 18S rDNA) was observed in any cardiac samples at 2, 8, or 12 weeks post-injection of rAAV6[mito-ApaLI-HA] when compared with samples from mice injected with rAAV6[AP] ( Figure 3a ).
Heart sections from mice injected with rAAV6[mito-ApaLI-HA] were evaluated for COX deficiency using immunofluorescence with an antibody against MT-CO1, an mtDNA-encoded catalytic subunit of COX. No evidence of loss of MT-CO1 staining or an increase in SDHA staining, indicative of mtDNA-related OXPHOS dysfunction, was seen in any of the transduced fibers at 12 weeks post-injection ( Figure 2c ). No alterations in MT-CO1 or SDHA expression were observed in samples of mice injected with the control rAAV6[AP] vector ( Figure  2c ). No evidence of morphological abnormalities after H&E staining was observed in mice injected with either AAV vector at 12 weeks post-injection (data not shown).
Liver expression of rAd5[mito-ApaLI-HA]-no mtDNA depletion nor COX deficiency observed in heteroplasmic mice
Similar analysis of liver DNA taken from mice injected with either rAd5[mito-ApaLI-HA] or rAd5[eGFP] found no evidence of mtDNA depletion in the samples at 2 weeks post-injection. There was a transient reduction in mtDNA levels in mice injected with rAd5[mito-ApaLI-HA] at 1 week post-injection, but normal levels were observed by 2 weeks (Figure 3b ).
Fixed liver sections from mice injected with the adenoviral vectors were evaluated histochemically for COX activity. No COX-deficient areas were visible in samples from mice injected with rAd5[mito-ApaLI-HA] taken at 1 week (Figure 2b) or 2 weeks (data not shown) post-injection. In addition, no morphological abnormalities were observed with H&E staining at 2 weeks postinjection (data not shown).
Cardiac expression of rAAV6[mito-ApaLI-HA]mito-ApaLI-HA expression induces a shift in mtDNA heteroplasmy
Changes in mtDNA heteroplasmy were evaluated using radiolabeled RFLP after amplification using a RE ApaLI to investigate the levels of NZB mtDNA relative to BALB Inducing organ-specific shifts in mtDNA heteroplasmy SR Bacman et al mtDNA (NZB mtDNA is not cleaved by mito-ApaLI-HA). For mice injected with the AAV6 vectors, changes in NZB levels were determined by comparing the levels in skeletal muscle biopsies taken before injection on day 0 to levels in cardiac muscle samples taken at 2, 8, or 12 weeks post-injection ( Figure 4a ). We used skeletal muscle as the tissue of choice for baseline mtDNA heteroplasmy because, in this model, mtDNA heteroplasmy is stable over time in skeletal muscle, which has many functional and structural similarities to cardiac muscle. 20 A significant increase in the levels of NZB mtDNA was observed in all cardiac samples from mice injected with rAAV6[mito-ApaLI-HA] with the highest change seen at 12 weeks post-injection. No change was observed in mice receiving rAAV6[AP] at any time point (Figure 4a ). At 12 weeks post-delivery of rAAV6[mito-ApaLI-HA], changes in NZB levels were also examined in other tissues ( Figure 4b ). No significant change was seen in the percentage of NZB mtDNA at 12 weeks post-delivery of the transgene in spleen, brain, lung, kidney, gastrocnemius, triceps, quadriceps, soleus nor tibialis anterior muscles. A significant but small increase was observed in liver ( Figure 4b ).
Liver expression of rAd5[mito-ApaLI-HA]-mito-ApaLI-HA expression induces a shift in mtDNA heteroplasmy
For the mice injected with adenoviral vectors, liver samples for DNA extraction were taken on day 0 before injection and at 1 or 2 weeks post-injection. As shown in Figure 4c , the initial proportion of NZB mtDNA ranged from 4 to 70%. Samples from mice that received the rAd5[eGFP] control vector showed no change in the level of NZB mtDNA at 2 weeks post-injection. However, samples obtained from mice injected with rAd5[mito-ApaLI-HA] showed an increase in the levels of NZB mtDNA at 1 or 2 weeks post-injection. Note that the agerelated increase in relative levels of NZB mtDNA seen in liver in NZB/BALB mice is far less than observed here (compare the induced change with the natural drift shown in Supplementary Figure S1 ). We also determined whether there were any change in the percentage of NZB mtDNA in kidney and spleen that are not targeted by adenovirus. No increase in the relative levels of NZB mtDNA was seen in these tissues in any samples ( Figure 4d ).
Apparent reduction in ApaLI cleavage in post-injection samples is not caused by mutation of ApaLI sites
As ApaLI was used both to induce heteroplasmy shift in vivo and to diagnose heteroplasmy levels, it is possible Inducing organ-specific shifts in mtDNA heteroplasmy SR Bacman et al that apparent changes in heteroplasmy could be related to mutations of ApaLI sites caused by cleavage and defective repair rather than by a heteroplasmy shift. To investigate this, we sequenced the ApaLI site in pre-and post-injection samples from liver of an rAd5[mito-ApaLI-HA]-injected mouse. The only differences visible in electropherograms of the region in both the pre-and post-injection samples corresponded to the sequences expected from NZB or BALB haplotypes and not to novel mutations (Supplementary Figure S4 ). This confirms that the observed changes in ApaLI RFLP reflect changes in heteroplasmy.
Discussion
Human cells contain an average 1000 copies of mtDNA compared with the 2n copies of nuclear genome. 21 The concurrent existence of variable proportions of both wild-type and mutated mtDNA in cells of patients with heteroplasmic mtDNA mutations offers the potential for unique approaches to gene therapy. 22 The multicopy nature of the mitochondrial genome means that, rather than inserting wild-type versions of mutant genes or silencing them (as it is done with nuclear genes), the selective removal of mutant genomes is a viable strategy for gene therapy. This approach is termed heteroplasmy shift. It is now well established that REs targeted to mitochondria (mito-RE) are able to bring about heteroplasmy shift by stimulating the digestion of mtDNA with double-strand breaks (DSBs) and replication of residual Inducing organ-specific shifts in mtDNA heteroplasmy SR Bacman et al intact mtDNA. 13, 23 In mtDNA heteroplasmic models where a pathogenic mutation creates a unique restriction site not present on co-existent wild-type mtDNA, this cycle enables marked decreases in mutant load and recovery of OXPHOS function. 14, 15 Similarly, we have shown that local injection of rAd5[mito-ApaLI-HA] that targets only BALB mtDNA in the NZB/BALB mouse, leads to a localized heteroplasmy shift towards the NZB haplotype. 13 We have now explored the systemic delivery of mito-RE using tissue tropic viral vectors. MtDNA point mutations cause clinical symptoms when the percentage of wild-type DNA drops below a critical threshold, typically 10-40%. 24 The absolute levels of NZB mtDNA, representing wild-type mtDNA in our model, ranged from 6 to 70% with a mean of 30%, being a reasonable model for the levels of heteroplasmy seen in patients. Following expression of mito-ApaLI-HA, NZB mtDNA levels in liver ranged from 70 to 93% (mean 87%). Sequencing through the mitochondrial ApaLI restriction site region confirmed that the observed heteroplasmy shift was not due to cleavage-induced mutation. Heteroplasmy shift of this magnitude would typically be sufficient to reduce the mutant load and protect against a biochemical defect in different cell or tissue types. Nevertheless, in the cases that overall mutant load is very high, the wild-type levels would have to increase relatively fast to compensate for the loss of mutant mtDNA and restore function.
The degree and efficiency of heteroplasmy shift depends on the presence of a residual population of uncut mtDNA. In a 'differential multiple cleavage site model,' using a RE that recognized multiple sites on both mtDNA haplotypes in the NZB/BALB mouse, 16 we observed only slight changes in heteroplasmy and a transient mtDNA depletion caused by cutting of the entire mtDNA population in cells or tissue. As the mito-ApaLI-HA RE used in this study only cut BALB mtDNA, we observed larger changes in mtDNA heteroplasmy and no mtDNA depletion. There was a small mtDNA depletion in mice injected with rAd5[mito-ApaLI-HA] and sampled at 7 days, but no depletion was present at 14 days, a time where the vector would have been cleared. 25 The lack of observable COX deficiency in the samples with depletion is most likely due to the transient nature of the depletion and to the fact that the depletion was not severe enough to impair OXPHOS assembly. This is in agreement with the observation that it can take weeks for a detectable mtDNA depletion to manifest as an observable biochemical defect. 26 No evidence of partially deleted mtDNA species was found on either Southern blots or using PCR (data not shown). In systems where we have used mitochondria-targeted Figure 4 [mito-ApaLI-HA] induces a significant shift in mtDNA heteroplasmy in targeted tissues after systemic injection of the transgenes. The percentage of NZB mtDNA genotype was quantified by the last-cycle hot PCR/RFLP analysis (as described in Materials and methods). (a) DNA samples from injected animals with rAAV6[AP] or rAAV6[mito-ApaLI-HA] were evaluated for the increase of NZB mtDNA after 2 weeks (2w), 8 weeks (8w), and 12 weeks (12w) systemic delivery of the transgenes (one animal per group, six animals total). Significant increase of the NZB mtDNA was observed in heart after injection of rAAV6[mito-ApaLI-HA] over time, with no change when the control rAAV6[AP] virus was delivered (three independent samples from the same mouse *Po0.05). (b) Because of the natural increase of NZB mtDNA in liver and kidney, and decrease in spleen (S1), 20 the NZB mtDNA ratio from samples obtained after delivery of the rAAV6[mito-ApaLI-HA] were normalized to the rAAV6[AP]-injected samples, and the ratios were compared with muscle samples before the injection. Only liver and heart showed significantly increased NZB mtDNA above 1, when compared with muscle-pre-injected tissue after 12 weeks (three independent samples from the same mouse *Po0.05). Inducing organ-specific shifts in mtDNA heteroplasmy SR Bacman et al REs that cleave all the mtDNA in cells or tissues, we have observed DSB-induced recombination and the production of partially deleted mtDNAs, albeit at low levels. [27] [28] [29] The absence of such mtDNA species in this study mirrors the findings of earlier work with mito-ApaLI-HA and is probably due to the efficient repletion of mtDNA via replication of the pool of uncut NZB mtDNA blocking the fixation of rare BALB recombination events. 13 Numerous serotypes of AAV have been identified that have different tissue tropisms and binding characteristics. 17 An elegant analysis of AAV serotypes 1-9 was performed using bioluminescence imaging to compare spatial and temporal differences in reporter gene expression from the different serotypes following systemic administration. 18 AAV6 was found to transduce heart, skeletal muscle, liver, and lung with expression reaching plateau at about 8 weeks when 1 Â 10e11 viral particles were administered through the tail vein. 18 We were unable to detect AP expression in liver and lung. Expression in heart was barely detectable at 2 weeks but strong at 8 and 12 weeks post-administration of rAAV6[AP]. Heteroplasmy shift was already detectable in heart at 2 weeks post-injection of rAAV6[mito-ApaLI-HA] and increased until 12 weeks. A small change in heteroplasmy was seen in skeletal muscle, only detectable at 8 weeks post-injection. HA expression in skeletal muscle was weak at 8 and 12 weeks post-injection, only detected by immunohistochemistry. Apparent variations in spatial and temporal expression of AP and mito-ApaLI-HA most likely reflect differences in expression assays as AP is detected as total activity at a given time point, whereas mito-ApaLI-HA is detected as a cumulative heteroplasmy shift over the course of an experiment. The tissue tropism of rAAV6[mito-ApaLI-HA] as determined by heteroplasmy shift is in accordance with the results obtained by Yang et al. 30 that showed high reporter gene expression in the heart following tail vein injection of AAV6. Similar results were obtained by Palomeque et al. 17 who showed AAV6 vectors efficiently transduced rat myocardium reaching a plateau at 4 weeks post-injection. Skeletal muscle is clearly a relevant tissue for mtDNA gene therapy. High levels of transduction of skeletal muscle have been achieved using very high titers of AAV6 vectors 31 or in combination with VEGF as a vasodilator. 32 Adenovirus vectors are currently used in more clinical trials than any other viral vector [clinicaltrials.gov at NIH] due to their minimal toxic effect and lack of integration. [33] [34] [35] In rodents and non-human primates, systemic administration of rAd5 results in high transduction in liver. 19, [35] [36] [37] In addition, jugular vein injection appears to increase survival compared with tail vein injection. 38 Hepatotropism of Ad vectors is mediated via interactions with blood 25 and hepatocyte cell surface receptors. Reporter gene analysis and the observed heteroplasmy shift in liver but not kidney or spleen in this study are in accordance with the high hepatotropism of rAd5 vectors. As we did find evidence of a transient-mtDNA depletion in liver at 1 week, one could argue that the change in heteroplasmy could be related to the death of cells with a respiratory defect (mtDNA depletion) and subsequent regeneration of cells with a different mtDNA heteroplasmy state. However, we do not believe this is the case because we did not observe COX deficiency at any time point after injection. Although the robust change in mtDNA heteroplasmy observed in liver is likely to be long lasting, we have not performed long-term studies after rAd5[mito-ApaLI-HA].
The ease with which we were able to induce mtDNA heteroplasmy shift in different tissues, using unmodified vector systems with expression driven by simple cytomegalovirus (CMV) promoters, reflects the wideexpression profile of mito-ApaLI-HA that is capable of inducing heteroplasmy shift. This implies that partial removal of mutant mtDNA genomes can be achieved either through a short burst of high expression, as shown by rAd5[mito-ApaLI-HA] in liver or by longer-term/ lower-level expression of rAAV6[mito-ApaLI-HA] in the heart. There is no good evidence of any form of replicative advantage or selection toward mtDNA with pathogenic point mutations in vivo thus a shift in mtDNA heteroplasmy is likely to be long lasting. Off-site transduction of viral vectors (for example AAV6 expression in skeletal muscle and liver) probably would be desirable in the case of mitochondrial disease, which are commonly multisystemic disorders.
Among potential therapies to treat mitochondrial diseases associated with mtDNA mutations, changes in mtDNA heteroplasmy is arguably the most promising approach. The use of bacterial restriction nucleases is limited by the requirement that a unique site must be created by the mutation. However, we have shown that under controlled conditions, mtDNA with multiple sites can be differentially susceptible to degradation if one molecule harbors more sites than the other. 16 A related but broader approach would be the use of mitochondriatargeted zinc finger nucleases with designed recognition sites. 39 The current work should stimulate research into the therapeutic potential of mitochondrial nucleases in heteroplasmic mtDNA disorders.
Materials and methods
Mito-ApaLI-HA constructs
A synthetic gene coding for the ApaLI RE with a C-terminal HA (Hemagglutinin antigen) tag was purchased from Integrated DNA Technologies (Coralville, IA, USA). The codon usage was optimized for mammalian translation. An N-terminal mitochondrial import signal derived from COX8A was added, and the resulting construct was cloned into pAd5-Track for production of rAd5[mito-ApaLI-HA] adenoviral vectors. 13 The same insert was cloned in an adenovirus-associated viral vector (rAAV6[mito-ApaLI-HA]) for the production of viral particles (Supplementary Figure S2) . In both cases, expression was under the control of the CMV promoters. Respective CMV-driven control viral vectors expressing green fluorescent protein (rAd5[eGFP]), or alkaline phosphatase (rAAV6[AP]) were also produced.
NZB/BALB mice
Female NZB/BALB heteroplasmic founders were a kind gift from Eric Shoubridge (McGill University). 20 These mice carry variable levels of the NZB and BALB murine mtDNA haplotypes in a BALB genetic background and do not display any form of mitochondrial dysfunction.
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Virus administration and sample preparation
To achieve systemic delivery, anesthetized adult female mice (6-8 weeks old) were injected in the right external jugular vein. Viral vector concentration was determined by A260 measurements. 40 
Heteroplasmy analysis and Southern blotting
Total DNA from tissue samples was obtained after phenol-chloroform extraction. mtDNA heteroplasmy was determined by 'Last-cycle hot' PCR 42 using mtDNA primers (5228-5250; 5665-5690). The PCR product was digested with ApaLI, which digests BALB mtDNA at position 5461 and subjected to electrophoreses in an 8% polyacrylamide gel. The radioactive signal was quantified using a Cyclone phosphorimaging system (Perkin-Elmer, Waltham, MA, USA) as described. 16 For Southern blotting analysis, 5 mg of total DNA was digested with SacI, which linearized mouse mtDNA by cleavage at position 9047. Digested samples were electrophoresed through 0.8% agarose gels and transferred to zeta-probe membranes (Bio-Rad, Hercules, CA, USA). mtDNA was detected by hybridization with a probe corresponding to positions 10-10 145 of the mouse mtDNA (accession number AJ512208). To quantify nuclear DNA, the blots were hybridized with a probe corresponding to positions (502-1515) of the mouse 18S rDNA (accession number BK000964). The radioactive signal was quantified using a Cyclone phosphor-imager system as described earlier. 16 
Western blotting
A measure of 50 mg of total protein from liver or cell homogenates was electrophoresed using 4-20% Tris-HCl polyacrylamide gels (Bio-Rad) and transferred to nitrocellulose membranes (Bio-Rad). Rat anti-HA antibody was obtained from Roche Biochemicals and a donkey anti-rat IgG IRDye 800-conjugated secondary antibody from Rockland (Gilbertsville, PA, USA). The Odyssey Infrared Imaging System (LI-COR) was used to quantitate western blots.
Histological and immunohistochemical studies NZB/BALB mouse hepatocytes were plated onto coverslips and infected with 1 Â 10e3 viral genomes per cell of rAd5[mito-ApaLI-HA] or rAAV6[mito-ApaLI-HA] for 48 h. Cells were then incubated for 30 min at 37 1C with 200 nM Mito Tracker Red CMXRos (Invitrogen, Carlsbad, CA, USA) and fixed with 2% paraformaldehyde (PFA) in PBS for 20 min. After a brief treatment with methanol (5 min), a primary anti-HA antibody (Roche) (in 2% bovine serum albumin (BSA) in PBS) was left overnight at 4 1C followed by 2 h incubation at room temperature with an Alexa Fluor 488-conjugated secondary antibody (Molecular Probes, Invitrogen, Carlsbad, CA, USA). Images were recorded using a confocal microscope LSM510 from Carl Zeiss. Tissue samples were fixed in 4% PFA and cryopreserved using 30% sucrose in PBS before freezing in liquid nitrogen-cooled isopentane and stored at À80 1C. For staining, samples were sectioned using a cryostat (20 mm) and mounted on Superfrost Plus microscope slides (Thermo Fisher Scientific, Walthan, MA, USA). Samples from rAd5-injected mice were checked for eGFP expression. Tissue samples from rAAV6-injected mice were frozen in isopentane and sectioned (20 mm). Slices were fixed in 4% PFA, pre-heated for 90 min in PBS at 67 1C to eliminate the endogenous alkaline phosphatase and stained for alkaline phosphatase. Chromogenic staining was achieved by incubation with an NBT/BCIP solution (Sigma-Aldrich, St. Louis, MO, USA). Samples for immunofluorescence were treated with 0.5% Triton X-100 in PBS with 2% BSA for 30 min and then stained using anti-HA, anti-SDHA, or anti-MTCO1-Alex 594 conjugated as above. For histological studies, samples were frozen in isopentane, fixed in PFA 4% and stained for COX or COX/SDH activities as described. 43 
